Oliveira Rui Caetano, Gama João, Casanova José
Centro de Anatomia Patológica Germano de Sousa, 3000 Coimbra, Portugal.
Coimbra Institute for Clinical and Biomedical Research (iCBR), 3000 Coimbra, Portugal.
Explor Target Antitumor Ther. 2023;4(4):583-599. doi: 10.37349/etat.2023.00154. Epub 2023 Aug 24.
Targeting the B-cell lymphoma 2 (Bcl-2) family proteins has been the backbone for hematological malignancies with overall survival improvements. The Bcl-2 family is a major player in apoptosis regulation and, has captured the researcher's interest in the treatment of solid tumors. Sarcomas are a heterogeneous group of diseases, comprising several entities, with high morbidity and mortality and with few specific therapies available. The treatment for sarcomas is based on platinum regimens, with variable results and poor outcomes, especially in advanced lesions. The high number of different sarcoma entities makes treatment standardization as well as the performance of clinical trials difficult. The use of Bcl-2 family members modifiers has revealed promising results in and models and may be a valid option, especially when used in combination with chemotherapy. In this article, a revision of these results and possibilities for the use of Bcl-2 family members inhibitors in sarcomas was performed.
靶向B细胞淋巴瘤2（Bcl-2）家族蛋白一直是改善血液系统恶性肿瘤总生存期的主要手段。Bcl-2家族是细胞凋亡调控的主要参与者，已引起研究人员对实体瘤治疗的兴趣。肉瘤是一组异质性疾病，由多个实体组成，发病率和死亡率高，且可用的特异性疗法很少。肉瘤的治疗基于铂类方案，疗效不一且预后较差，尤其是在晚期病变中。不同肉瘤实体的数量众多，使得治疗标准化以及开展临床试验都很困难。在[具体模型1]和[具体模型2]模型中，使用Bcl-2家族成员调节剂已显示出有前景的结果，可能是一种有效的选择，尤其是与化疗联合使用时。在本文中，对这些结果以及Bcl-2家族成员抑制剂在肉瘤中的应用可能性进行了综述。
